SPL Mapping FHIR Implementation Guide
0.1.0 - Build CI United States of America flag

SPL Mapping FHIR Implementation Guide, published by HL7 International / Biomedical Research and Regulation. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-spl/ and changes regularly. See the Directory of published versions

Example Composition: These highlights do not include all the information needed to use ENBREL safely and effectively. See full prescribing information for ENBREL. <br/> <br/>ENBREL<sup>®</sup> (etanercept) injection, for subcutaneous use <br/>ENBREL<sup>®</sup> (etanercept) for injection, for subcutaneous use <br/>Initial U.S. Approval: 1998

Page standards status: Informative

Generated Narrative: Composition

Resource Composition "EnbrelSyringeLabelComposition"

Profile: ProductSubmissionDocument

VersionNumber: 197

identifier: Uniform Resource Identifier (URI)/urn:uuid:a002b40c-097d-47a5-957f-7a7b1807af7f

status: final

type: HUMAN PRESCRIPTION DRUG LABEL (LOINC#34391-3)

date: 2021-12-13

author: Organization/ImmunexCorporation "Immunex Corporation"

title: These highlights do not include all the information needed to use ENBREL safely and effectively. See full prescribing information for ENBREL. <br/> <br/>ENBREL<sup>®</sup> (etanercept) injection, for subcutaneous use <br/>ENBREL<sup>®</sup> (etanercept) for injection, for subcutaneous use <br/>Initial U.S. Approval: 1998